It is proposed that this article be deleted because of the following concern:
If you can address this concern by improving, copyediting, sourcing, renaming, or merging the page, please edit this page and do so. You may remove this message if you improve the article or otherwise object to deletion for any reason. Although not required, you are encouraged to explain why you object to the deletion, either in your edit summary or on the talk page. If this template is removed, do not replace it . The article may be deleted if this message remains in place for seven days, i.e., after 03:25, 26 March 2025 (UTC). Find sources: "Philip Radovic" – news · newspapers · books · scholar · JSTOR |
This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
Philip Radovic, physician (born March 27, 1958) is a professor and pediatric surgeon, who practices in South Orange County, California.
Radovic served as the lead instructor for the use of AbobotulinumtoxinA in the management of hallux valgus in adult patients. He conducted a randomized and placebo-controlled Phase 2 trial for this treatment. Radovic also led a Phase IIa study on the use of Dysport in hallux abducto valgus (HAV). [1]